Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma × Hydroxyurea × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 7 Glioblastoma 6 Squamous Cell Carcinoma of Head and Neck 5 Gliosarcoma 5 Meningioma 4 Leukemia, Myeloid, Acute 4 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Head and Neck Neoplasms 4 Polycythemia Vera 3 Neoplasms 3 Leukemia, Myeloid, Chronic-Phase 3 Glioma 3 Primary Myelofibrosis 2 Myelodysplastic Syndromes 2 Leukemia 2 Laryngeal Neoplasms 2 Esophageal Neoplasms 2 Central Nervous System Neoplasms 2 Tongue Neoplasms 1 Thrombosis 1 Thrombocytosis 1 Thrombocythemia, Essential 1 Stomach Neoplasms 1 Salivary Gland Neoplasms 1 Polycythemia 1 Pharyngeal Neoplasms 1 Paranasal Sinus Neoplasms 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1 Oropharyngeal Neoplasms 1

Interventions

Cisplatin 17 Gemcitabine 15 pembrolizumab 14 Radiotherapy 13 Paclitaxel 13 Radiotherapy, Intensity-Modulated 12 Carboplatin 10 Cyclophosphamide 9 Cetuximab 8 Magnetic Resonance Spectroscopy 7 Specimen Handling 6 Oxaliplatin 6 Fluorouracil 6 Docetaxel 6 Capecitabine 6 padeliporfin 5 Radiation 5 Irinotecan 5 Drug Therapy 5 poly ICLC 4 fludarabine 4 anlotinib 4 Standard of Care 4 Nivolumab 4 Leucovorin 4 Ipilimumab 4 Celecoxib 4 durvalumab 3 Sunitinib 3 Sorafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00468169 2019-10-09

EPIC

University of Chicago

Phase 2 Completed

110 enrolled 14 charts

Carcinoma, Head and Neck Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡